# Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation

Authors: Kazuyuki Numakura; Hideaki Kagaya; Ryohei Yamamoto; Naoki Komine; Mitsuru Saito; Tsuruta Hiroshi; Susumu Akihama; Takamitsu Inoue; Shintaro Narita; Norihiko Tsuchiya; Tomonori Habuchi; Takenori Niioka; Masatomo Miura; Shigeru Satoh
Journal: Disease Markers
 (2015)

---

## Abstract

We determined the prevalence of dyslipidemia in a Japanese cohort of renal allograft recipients and investigated clinical and genetic characteristics associated with having the disease. In total, 126 patients that received renal allograft transplants between February 2002 and August 2011 were studied, of which 44 recipients (34.9%) were diagnosed with dyslipidemia at 1 year after transplantation. Three clinical factors were associated with a risk of having dyslipidemia: a higher prevalence of disease observed among female than male patientsP
=
0.021 and treatment with high mycophenolate mofetil P
=
0.012 and prednisolone P
=
0.023 doses per body weight at 28 days after transplantation. The genetic association between dyslipidemia and 60 previously described genetic polymorphisms in 38 putative disease-associated genes was analyzed. The frequency of dyslipidemia was significantly higher in patients with the glucocorticoid receptor (NR3C1) Bcl1 G allele than in those with the CC genotype P
=
0.001. A multivariate analysis revealed that the NR3C1 Bcl1 G allele was a significant risk factor for the prevalence of dyslipidemia (odds ratio = 4.6; 95% confidence interval = 1.8–12.2). These findings may aid in predicting a patient’s risk of developing dyslipidemia.


---

## Body

## 1. Introduction

Dyslipidemia is a disorder of lipid metabolism and is characterized by elevated levels of lipid in the bloodstream. It is frequently observed in renal transplant recipients [1] and is a risk factor for cardiovascular disease and graft loss [2]. Prior to current immunosuppressive practices, the prevalence of dyslipidemia in renal transplant recipients was over 80% [3]; however, despite new interventions, the risk of disease remains at 44% to 60% [4]. There are a number of previously described risk factors for the development of dyslipidemia in renal transplant recipients, including diet and age; however, a number of therapeutic interventions associated with the transplantation, including steroid, cyclosporine (CyA), and mTOR inhibitor treatments, increase the risk of developing dyslipidemia [5].Steroids influence cholesterol metabolism by activating acetyl-CoA carboxylase, hydroxymethylglutaryl-CoA reductase, and free fatty acid synthase, decreasing the activity of the low-density lipoprotein (LDL) receptor, and inhibiting lipoprotein lipase [6]. Consequently, steroid-based treatments such as steroid pulse therapy result in an increase of very low-density lipoproteins (VLDL), total cholesterol (TC), and triglyceride (TG) and a decrease of high-density lipoprotein (HDL). To avoid this, an early reduction in steroid treatment has been shown to reduce the incidence of dyslipidemia [7]. CyA is administered to transplant recipients to minimize graft rejection by inhibiting the growth and action of T cells. It has also been shown to inhibit 26-hydroxylase, a key enzyme involved in bile acid synthesis, which results in a decrease of cholesterol secretion into the intestine and a development of dyslipidemia [8]. Tacrolimus (TAC), a calcineurin inhibitor, reduces the incidence of dyslipidemia more than CyA (CyA, 36% versus TAC, 26%) [9]. Treatment with steroids and CyA has a synergistic effect that results in an increase in TC levels [10]. mTOR inhibitors, which are also commonly administered as an immunosuppressant, increase both TC and TG levels and inhibit the metabolism of apolipoprotein B100 in a dose-dependent manner. Inhibition of mTOR leads to a reduction in insulin secretion and insulin-like growth factor, which results in an increase in lipid synthesis within liver cells [11].Since 1998, renal transplant recipients at our institute, who were all Japanese, have been treated under the same TAC-based immunosuppressive regimen. As is well known, there is marked individual diversity of blood TAC, mycophenolate mofetil (MMF), and steroid concentration after transplantation [12–14]. These genetic polymorphisms may influence individual variations in pharmacokinetics of immunosuppressive drugs. However, the association between drug pharmacokinetics and its related genetic polymorphisms with the prevalence of dyslipidemia under the TAC-based immunosuppression has not been definitively established.The aim of this study was to determine the prevalence of dyslipidemia in a Japanese cohort and determine clinical and genetic characteristics associated with disease risk within the first year after transplantation under the TAC, MMF, and steroid therapy. A number of genetic polymorphisms that are associated with lipid metabolism have been previously described [15, 16]. In this study, 60 polymorphisms in 38 genes known to be involved in lipid metabolism were examined to determine their association with the development of dyslipidemia.


## 2. Materials and Methods

### 2.1. Patients and Diagnosis of Dyslipidemia

One hundred and twenty-six adult patients who (i) received a renal allograft under TAC-based immunosuppression at Akita University Hospital between February 2002 and August 2011, (ii) had no serious complications, and (iii) maintained graft function for at least one year after transplantation were eligible for this study. From this patient cohort, individuals with high LDL cholesterol levels (≥140 mg/dL), hypertriglyceridemia (≥TG 150 mg/dL), and low HDL cholesterol levels (<40 mg/dL) in the first year after transplantation, or those who required oral statin treatment, were defined as having dyslipidemia.


### 2.2. Immunosuppressive Therapy

Patients initially received combination immunosuppressive therapy consisting of TAC, MMF, and steroid. An initial oral dose (0.15 mg/kg) of TAC and 1.5–2.0 g/day of MMF were administered in two equally divided doses every 12 h at a designated time (09:00 and 21:00). The daily TAC dose was adjusted to achieve a whole blood trough level as previously reported [17]. Methylprednisolone was given concomitantly; a dose of 500 mg on the day of surgery was initially administered and was subsequently tapered to 40 mg/day during the first week, 20 mg/day of prednisolone in the second week, 15 mg/day of prednisolone in the third week, and 10 mg/day thereafter. In the maintenance stage, the dose of prednisolone ranged from 2.5 to 10.0 mg/day based on the immunosuppressive state of each patient. After July 2004, all patients received basiliximab (20 mg) intravenously on the day of surgery and on postoperative day 4. Patients that were ABO-incompatible or were receiving a second transplantation initially received MMF starting in 21 days and TAC and steroids starting 7 days prior to surgery. These patients either underwent a splenectomy at the time of transplantation or were administered rituximab (200 mg/body weight) intravenously (since 2005).


### 2.3. Evaluation of Renal Function

Renal function was evaluated based on the estimated glomerular filtration rate (eGFR). The eGFR was calculated using the following equation established for the Japanese population:(1)
eGFR
(
mL
/
min
⁡
/
1.732
m
2
)
=
194
×
Serum
creatinine
-
1.094
×
Age
-
0.287
×
0.739
(
if
female
)
.


### 2.4. Evaluation of the Pharmacokinetic Profiles of TAC, MMF, and Steroid

On day 28 after renal transplantation, the whole blood samples were collected immediately prior to and 1, 2, 3, 6, 9, and 12 h after the morning oral administration of TAC, MMF, and steroid. The concentration of TAC in the blood samples was measured by a microparticle enzyme immunoassay (IMx Abbott Laboratories, Abott Park, IL) performed in duplicate, and the concentration of mycophenolic acid, which is active metabolite of MMF, was measured by high-performance liquid chromatography. Pharmacokinetic analysis of prednisolone was carried out with a standard noncompartmental method using WinNonlin (Pharsight Co., Mountain View, CA, USA, version 4.0.1). The pharmacokinetics was estimated as previously reported [12, 17].


### 2.5. Genotyping of Genomic Polymorphisms

DNA was extracted from a peripheral blood sample using QIAamp Blood kit (Qiagen, Hilden, Germany) and was stored at −4°C until analysis. Primer sequences and polymerase chain reaction (PCR) conditions for the analysis of each polymorphism were performed according to previous reports [12, 18–29]. All polymorphisms were analyzed by the PCR-restriction fragment length polymorphism (RFLP) method.


### 2.6. Statistical Analysis

Chi-square tests were used to test categorical data, whereas Mann-WhitneyU tests were employed to analyze continuous values between groups. P values less than 0.05 were considered to be statistically significant. A logistic regression analysis was used to perform multivariate analyses. Clinical and genetic variables were included in the multivariate analyses if their univariate P value was less than 0.10. The analysis was performed using SPSS version 19.0 statistical software (SPSS Japan Inc., Tokyo, Japan). To test the population homogeneity of the subjects, the genotype frequencies of each polymorphism were tested against the Hardy-Weinberg equilibrium using a chi-square test.


## 2.1. Patients and Diagnosis of Dyslipidemia

One hundred and twenty-six adult patients who (i) received a renal allograft under TAC-based immunosuppression at Akita University Hospital between February 2002 and August 2011, (ii) had no serious complications, and (iii) maintained graft function for at least one year after transplantation were eligible for this study. From this patient cohort, individuals with high LDL cholesterol levels (≥140 mg/dL), hypertriglyceridemia (≥TG 150 mg/dL), and low HDL cholesterol levels (<40 mg/dL) in the first year after transplantation, or those who required oral statin treatment, were defined as having dyslipidemia.


## 2.2. Immunosuppressive Therapy

Patients initially received combination immunosuppressive therapy consisting of TAC, MMF, and steroid. An initial oral dose (0.15 mg/kg) of TAC and 1.5–2.0 g/day of MMF were administered in two equally divided doses every 12 h at a designated time (09:00 and 21:00). The daily TAC dose was adjusted to achieve a whole blood trough level as previously reported [17]. Methylprednisolone was given concomitantly; a dose of 500 mg on the day of surgery was initially administered and was subsequently tapered to 40 mg/day during the first week, 20 mg/day of prednisolone in the second week, 15 mg/day of prednisolone in the third week, and 10 mg/day thereafter. In the maintenance stage, the dose of prednisolone ranged from 2.5 to 10.0 mg/day based on the immunosuppressive state of each patient. After July 2004, all patients received basiliximab (20 mg) intravenously on the day of surgery and on postoperative day 4. Patients that were ABO-incompatible or were receiving a second transplantation initially received MMF starting in 21 days and TAC and steroids starting 7 days prior to surgery. These patients either underwent a splenectomy at the time of transplantation or were administered rituximab (200 mg/body weight) intravenously (since 2005).


## 2.3. Evaluation of Renal Function

Renal function was evaluated based on the estimated glomerular filtration rate (eGFR). The eGFR was calculated using the following equation established for the Japanese population:(1)
eGFR
(
mL
/
min
⁡
/
1.732
m
2
)
=
194
×
Serum
creatinine
-
1.094
×
Age
-
0.287
×
0.739
(
if
female
)
.


## 2.4. Evaluation of the Pharmacokinetic Profiles of TAC, MMF, and Steroid

On day 28 after renal transplantation, the whole blood samples were collected immediately prior to and 1, 2, 3, 6, 9, and 12 h after the morning oral administration of TAC, MMF, and steroid. The concentration of TAC in the blood samples was measured by a microparticle enzyme immunoassay (IMx Abbott Laboratories, Abott Park, IL) performed in duplicate, and the concentration of mycophenolic acid, which is active metabolite of MMF, was measured by high-performance liquid chromatography. Pharmacokinetic analysis of prednisolone was carried out with a standard noncompartmental method using WinNonlin (Pharsight Co., Mountain View, CA, USA, version 4.0.1). The pharmacokinetics was estimated as previously reported [12, 17].


## 2.5. Genotyping of Genomic Polymorphisms

DNA was extracted from a peripheral blood sample using QIAamp Blood kit (Qiagen, Hilden, Germany) and was stored at −4°C until analysis. Primer sequences and polymerase chain reaction (PCR) conditions for the analysis of each polymorphism were performed according to previous reports [12, 18–29]. All polymorphisms were analyzed by the PCR-restriction fragment length polymorphism (RFLP) method.


## 2.6. Statistical Analysis

Chi-square tests were used to test categorical data, whereas Mann-WhitneyU tests were employed to analyze continuous values between groups. P values less than 0.05 were considered to be statistically significant. A logistic regression analysis was used to perform multivariate analyses. Clinical and genetic variables were included in the multivariate analyses if their univariate P value was less than 0.10. The analysis was performed using SPSS version 19.0 statistical software (SPSS Japan Inc., Tokyo, Japan). To test the population homogeneity of the subjects, the genotype frequencies of each polymorphism were tested against the Hardy-Weinberg equilibrium using a chi-square test.


## 3. Results

### 3.1. Patient Characteristics and Clinical Factors

The mean age of the transplant recipients at the time of transplantation was 47.3 years (range, 21–70 years), the dialysis duration was 48.6 months with a range of 0–420 months, and the mean posttransplant follow-up period was 47.5 months (range, 10–125 months). The primary renal diseases among the patient cohort were chronic glomerulonephritis, including IgA nephropathy (n
=
50), diabetes nephropathy (n
=
15), polycystic kidney disease (n
=
8), pregnancy toxicosis (n
=
5), reflux nephropathy (n
=
5), nephrosclerosis (n
=
3), lupus nephritis (n
=
3), and nephrosclerosis (n
=
2). Four cases were defined as “other,” and 31 cases were uncharacterized.Within the first year after transplantation, 44 patients (34.9%) were diagnosed with dyslipidemia. The clinical characteristics of patients with and without dyslipidemia are summarized in Table1. Females had a significantly higher prevalence of dyslipidemia over male patients. There were no significant differences in other clinical factors, including the mean body mass index, dialysis duration prior to transplantation, and eGFR at 1 year after transplantation.Table 1
Comparison of clinical characteristics between patients with dyslipidemia and without dyslipidemia.
With dyslipidemia (n = 44)
Without dyslipidemia (n = 82)
P
At transplantation
Age (yrs)
49.2 ± 10.3
46.3 ± 12.8
0.205
Gender (male : female)
21 : 23
57 : 25
0.021
BMI (kg/m2)
22.0 ± 3.5
22.6 ± 4.0
0.421
Dialysis duration (mos)
47.9 ± 54.6
49.0 ± 73.9
0.936
Donor age (yrs)
55.7 ± 12.7
58.4 ± 10.1
0.219
ABO incompatible
16
16
0.162
HCV antibody positive
1
2
0.970
1 yr after transplantation
CMV infection
11
16
0.700
Acute rejection
17
30
0.951
DM
13
22
0.777
Hypertension
32
62
0.773
Hyperuricemia
18
40
0.354
eGFR
54.1 ± 14.1
51.0 ± 14.7
0.306
Chi-square tests were used to test categorical data, whereas Mann-WhitneyU tests were employed to analyze continuous values between groups.
P values less than 0.05 were considered to be statistically significant.
Values are expressed as mean ± SD.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; CMV, cytomegalovirus; DM, diabetes mellitus.


### 3.2. Pharmacokinetics of TAC, MMF, and Steroid

An analysis of the pharmacokinetics of the immunosuppressive drugs revealed that the dose per body weight of MMF and steroid was higher in the transplant recipients with dyslipidemia than in patients without the disease at 28 days after transplantation (25.9 ± 7.1 versus 22.3 ± 6.9;P
=
0.012, 0.20 ± 0.05 versus 0.019 ± 0.03; P
=
0.023, resp.) (Table 2).Table 2
Comparison of pharmacokinetic parameters (TAC, MMF, and steroid) between patients with and without dyslipidemia.
Drug
Parameters
After one month
P
With dyslipidemia
Without dyslipidemia
TAC
Dose/BW (mg/kg/day)
0.17 ± 0.08
0.20 ± 0.10
0.679
AUC
0
–
12 (ng·hr/mL)
170.0 ± 34.6
187.4 ± 46.3
0.457
C
max
⁡ (ng/mL)
18.6 ± 4.7
21.1 ± 6.7
0.166
Trough
9.2 ± 3.2
9.9 ± 3.3
0.518
MMF
Dose/BW (mg/kg/day)
25.9 ± 7.1
22.3 ± 6.9
0.012
AUC
0
–
12 (ng·hr/mL)
46.0 ± 26.8
46.2 ± 18.7
0.611
C
max
⁡ (ng/mL)
9.3 ± 5.5
9.0 ± 4.9
0.716
Trough
3.9 ± 2.3
2.8 ± 1.7
0.192
Steroid
Dose/BW (mg/kg/day)
0.20 ± 0.05
0.19 ± 0.03
0.023
AUC
0
–
24 (ng·hr/mL)
1051.1 ± 426.9
1059.1 ± 407.4
0.936
C
max
⁡ (ng/mL)
130.9 ± 45.9
141.3 ± 46.5
0.375
Trough
0.9 ± 2.6
2.4 ± 8.5
0.549
Mann-WhitneyU tests were employed to analyze continuous values between groups.
P values less than 0.05 were considered to be statistically significant.
Values are expressed as mean ± SD.
TAC, tacrolimus; MMF, mycophenolate mofetil; BW, body weight; AUC, area under the concentration-time curve;C
max
⁡, maximal concentration.


### 3.3. Genetic Associations with Dyslipidemia

The association between having dyslipidemia and 60 polymorphisms in 38 genes was analyzed. These genes included known mediators of lipid metabolism (12 polymorphisms in 9 genes), cytokines (16 polymorphisms in 10 genes), and drug metabolism (32 polymorphisms in 19 genes). In seventeen polymorphisms, there were no variant alleles in this population (Table3). The genotype frequencies at the glucocorticoid receptor (NR3C1)Bcl1 loci were 78CC (61.9%), 45CG (35.7%), and 3GG (2.4%). Patients with dyslipidemia had a significantly higher frequency of theNR3C1 Bcl1 G allele (dyslipidemia, 25, nondyslipidemia, 23) than in those with theCC genotype (dyslipidemia, 19, nondyslipidemia, 59) (P
=
0.001) (Table 3).Table 3
Association of pharmacokinetics, cytokines, and dyslipidemia-related polymorphisms.
Number
Gene
Polymorphisms
Categories
OR
95% CI
P
1
IL-2
T-330G
G allele
0.482
0.157–1.480
0.200
2
IL-2Rβ
C-627T
T allele
0.591
0.187–1.867
0.545
3
IL-4
C-590T
TT genotype
0.952
0.316–2.873
0.931
4
IL-10
A-592C
C allele
0.912
0.299–2.784
0.872
5
IL-12B
A1188C
C allele
1.156
0.272–4.905
0.861
6
TNF-α
G-238A
A allele
—
—
1.000
G-308A
A allele
—
—
1.000
7
INFγ
A874T
T allele
—
—
1.000
8
TGF-β1
Codon 10 T/C
CC genotype
1.225
0.322–4.667
0.964
Codon 25 G/C
C allele
—
—
1.000
C-509T
TT genotype
0.719
0.203–2.543
0.844
9
CRP
T-717C
C allele
1.474
0.268–8.092
0.993
G1059C
C allele
2.289
0.349–15.010
0.686
C1444T
T allele
0.926
0.228–3.765
0.804
C1846T
TT genotype
1.067
0.358–3.182
0.908
10
HNF1α
Ileu27Leu
Leu/Leu genotype
0.857
0.318–2.310
0.760
Ala98Val
Val allele
—
—
1.000
11
Adiponectin
T45G
G allele
2.000
0.659–6.066
0.341
G276T
T allele
0.889
0.236–3.351
0.869
12
PPARα
Val227Ala
Ala allele
—
—
1.000
13
PPARγ
Pro12Ala
Ala allele
2.000
0.115–34.824
0.866
C161T
T allele
2.036
0.518–7.995
0.565
14
PPARγ coactivator1
Gly482Ser
Ser/ser genotype
3.250
0.480–21.998
0.438
G394A
A allele
0.381
0.073–1.992
0.449
15
Clock gene
T3111C
C allele
—
—
0.876
16
ACE
I/D
Deletion
1.270
0.381–4.230
0.697
17
ATIIR
A1166C
C allele
0.454
0.105–1.955
0.464
18
KCNJ11
E23K
A allele
0.571
0.185–1.765
0.329
19
SUR1
C-3T
TT genotype
0.286
0.081–1.008
0.946
20
UGT1A1
Promoter TA-repeat
*
6 allele
0.729
0.299–1.777
0.486
21
UGT1A6*2
*
1/
*
2
*
2 allele
0.955
0.255–3.576
0.789
22
UGT1A7
Codon 208
*
1/
*
3
*
3 allele
1.280
0.228–7.187
0.873
23
UGT1A8*2
codon173 A/G
GG genotype
1.176
0.507–2.732
0.705
24
UGT1A8*3
codon277 C/Y
Y allele
—
—
1.000
25
UGT1A9
C-2152T
T allele
—
—
1.000
T-275A
A allele
—
—
1.000
C1399T
TT genotype
1.126
0.485–2.617
0.783
26
UGT1A9*3
T98C
C allele
—
—
1.000
27
UGT2B7
C802T
T allele
0.770
0.330–1.795
0.545
28
CYP2C9*2
C430T
T allele
—
—
1.000
29
CYP2C9*3
A1075C
C allele
2.741
0.715–10.509
0.242
30
CYP2C19
*
1/
*
2/
*
3
*
2/
*
2,
*
2/
*
3,
*
3/
*
3
0.697
0.220–2.208
0.739
31
CYP3A4
*
1/
*
18
*
18 allele
—
—
1.000
G20230A
A allele
0.551
0.235–1.294
0.169
32
CYP3A5
A6985G
GG genotype
1.815
0.773–4.263
0.169
33
MDR-1
C1236T
TT genotype
1.067
0.291–3.916
0.814
C3435T
T allele
0.868
0.200–3.766
0.850
G2677T·A
T or A allele
0.688
0.152–3.102
0.922
34
OATP1B1
A388G
GG genotype
1.143
0.482–2.712
0.762
G455A
A allele
—
—
1.000
T521C
C allele
0.593
0.226–1.551
0.284
G721A
A allele
—
—
1.000
35
OATP1B3
T334G
GG genotype
1.176
0.507–2.732
0.705
G699A
AA genotype
0.714
0.242–2.108
0.542
Deletion A
Deletion
1.309
0.310–5.534
0.714
36
OATP2B1
*
1/
*
3
*
3 allele
0.936
0.402–2.176
0.877
37
Glucocorticoid receptor
Bcl I C/G
G allele
3.375
1.568–7.266
0.001
ER22/23EK
EK allele
—
—
1.000
N363S
S allele
—
—
1.000
38
CES2
rs2303218
AA genotype
2.700
0.697–10.465
0.146
rs3890213
A allele
3.429
0.791–14.854
0.190
IL, interleukin; TNF, tumor necrosis factor; INF, interferon; TGF, transforming growth factor; CRP, C-reactive protein; HNF, hepatocyte nuclear factor; PPAR, peroxisome proliferator-activated receptor; ACE, angiotensin-converting enzyme; ATIIR, angiotensin type 2 receptor; KCNJ, potassium inwardly rectifying channel, subfamily J; SUR, sulfonylurea receptor; UGT, uridine diphosphate-glucuronosyltransferase; CYP, cytochrome P450; MDR, multidrug resistance; OATP, organic anion transporting polypeptide; CES, carboxylesterase; OR, odds ratio; CI, confidence interval.


### 3.4. Multivariate Analysis

In the univariate analysis, female gender, dose per body weight of steroid and MMF, andNR3C1 Bcl1 G allele were associated with dyslipidemia. Multivariate analyses of the genotype data further supported the correlation of the presence of theNR3C1 Bcl1 G allele (odds ratio, 4.671, P
=
0.025) with dyslipidemia (Table 4).Table 4
Multivariate analysis of risk factors for dyslipidemia.
Factors
Categories
Univariate
Multivariate
OR
P
OR
95% CI
P
NR3C1 Bcl I
G allele
4.607
0.001
4.671
1.795–12.156
0.025
MMF/BW
≥24.2
2.902
0.027
2.212
0.771–6.350
0.375
Steroid/BW
≥0.188
2.526
0.034
1.126
0.389–3.256
0.843
Gender
Female
2.494
0.021
1.779
0.633–5.000
0.878
NR3C1, glucocorticoid receptor; BW, body weight; MMF, mycophenolate mofetil; OR, odds ratio; CI, confidence interval.


## 3.1. Patient Characteristics and Clinical Factors

The mean age of the transplant recipients at the time of transplantation was 47.3 years (range, 21–70 years), the dialysis duration was 48.6 months with a range of 0–420 months, and the mean posttransplant follow-up period was 47.5 months (range, 10–125 months). The primary renal diseases among the patient cohort were chronic glomerulonephritis, including IgA nephropathy (n
=
50), diabetes nephropathy (n
=
15), polycystic kidney disease (n
=
8), pregnancy toxicosis (n
=
5), reflux nephropathy (n
=
5), nephrosclerosis (n
=
3), lupus nephritis (n
=
3), and nephrosclerosis (n
=
2). Four cases were defined as “other,” and 31 cases were uncharacterized.Within the first year after transplantation, 44 patients (34.9%) were diagnosed with dyslipidemia. The clinical characteristics of patients with and without dyslipidemia are summarized in Table1. Females had a significantly higher prevalence of dyslipidemia over male patients. There were no significant differences in other clinical factors, including the mean body mass index, dialysis duration prior to transplantation, and eGFR at 1 year after transplantation.Table 1
Comparison of clinical characteristics between patients with dyslipidemia and without dyslipidemia.
With dyslipidemia (n = 44)
Without dyslipidemia (n = 82)
P
At transplantation
Age (yrs)
49.2 ± 10.3
46.3 ± 12.8
0.205
Gender (male : female)
21 : 23
57 : 25
0.021
BMI (kg/m2)
22.0 ± 3.5
22.6 ± 4.0
0.421
Dialysis duration (mos)
47.9 ± 54.6
49.0 ± 73.9
0.936
Donor age (yrs)
55.7 ± 12.7
58.4 ± 10.1
0.219
ABO incompatible
16
16
0.162
HCV antibody positive
1
2
0.970
1 yr after transplantation
CMV infection
11
16
0.700
Acute rejection
17
30
0.951
DM
13
22
0.777
Hypertension
32
62
0.773
Hyperuricemia
18
40
0.354
eGFR
54.1 ± 14.1
51.0 ± 14.7
0.306
Chi-square tests were used to test categorical data, whereas Mann-WhitneyU tests were employed to analyze continuous values between groups.
P values less than 0.05 were considered to be statistically significant.
Values are expressed as mean ± SD.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; CMV, cytomegalovirus; DM, diabetes mellitus.


## 3.2. Pharmacokinetics of TAC, MMF, and Steroid

An analysis of the pharmacokinetics of the immunosuppressive drugs revealed that the dose per body weight of MMF and steroid was higher in the transplant recipients with dyslipidemia than in patients without the disease at 28 days after transplantation (25.9 ± 7.1 versus 22.3 ± 6.9;P
=
0.012, 0.20 ± 0.05 versus 0.019 ± 0.03; P
=
0.023, resp.) (Table 2).Table 2
Comparison of pharmacokinetic parameters (TAC, MMF, and steroid) between patients with and without dyslipidemia.
Drug
Parameters
After one month
P
With dyslipidemia
Without dyslipidemia
TAC
Dose/BW (mg/kg/day)
0.17 ± 0.08
0.20 ± 0.10
0.679
AUC
0
–
12 (ng·hr/mL)
170.0 ± 34.6
187.4 ± 46.3
0.457
C
max
⁡ (ng/mL)
18.6 ± 4.7
21.1 ± 6.7
0.166
Trough
9.2 ± 3.2
9.9 ± 3.3
0.518
MMF
Dose/BW (mg/kg/day)
25.9 ± 7.1
22.3 ± 6.9
0.012
AUC
0
–
12 (ng·hr/mL)
46.0 ± 26.8
46.2 ± 18.7
0.611
C
max
⁡ (ng/mL)
9.3 ± 5.5
9.0 ± 4.9
0.716
Trough
3.9 ± 2.3
2.8 ± 1.7
0.192
Steroid
Dose/BW (mg/kg/day)
0.20 ± 0.05
0.19 ± 0.03
0.023
AUC
0
–
24 (ng·hr/mL)
1051.1 ± 426.9
1059.1 ± 407.4
0.936
C
max
⁡ (ng/mL)
130.9 ± 45.9
141.3 ± 46.5
0.375
Trough
0.9 ± 2.6
2.4 ± 8.5
0.549
Mann-WhitneyU tests were employed to analyze continuous values between groups.
P values less than 0.05 were considered to be statistically significant.
Values are expressed as mean ± SD.
TAC, tacrolimus; MMF, mycophenolate mofetil; BW, body weight; AUC, area under the concentration-time curve;C
max
⁡, maximal concentration.


## 3.3. Genetic Associations with Dyslipidemia

The association between having dyslipidemia and 60 polymorphisms in 38 genes was analyzed. These genes included known mediators of lipid metabolism (12 polymorphisms in 9 genes), cytokines (16 polymorphisms in 10 genes), and drug metabolism (32 polymorphisms in 19 genes). In seventeen polymorphisms, there were no variant alleles in this population (Table3). The genotype frequencies at the glucocorticoid receptor (NR3C1)Bcl1 loci were 78CC (61.9%), 45CG (35.7%), and 3GG (2.4%). Patients with dyslipidemia had a significantly higher frequency of theNR3C1 Bcl1 G allele (dyslipidemia, 25, nondyslipidemia, 23) than in those with theCC genotype (dyslipidemia, 19, nondyslipidemia, 59) (P
=
0.001) (Table 3).Table 3
Association of pharmacokinetics, cytokines, and dyslipidemia-related polymorphisms.
Number
Gene
Polymorphisms
Categories
OR
95% CI
P
1
IL-2
T-330G
G allele
0.482
0.157–1.480
0.200
2
IL-2Rβ
C-627T
T allele
0.591
0.187–1.867
0.545
3
IL-4
C-590T
TT genotype
0.952
0.316–2.873
0.931
4
IL-10
A-592C
C allele
0.912
0.299–2.784
0.872
5
IL-12B
A1188C
C allele
1.156
0.272–4.905
0.861
6
TNF-α
G-238A
A allele
—
—
1.000
G-308A
A allele
—
—
1.000
7
INFγ
A874T
T allele
—
—
1.000
8
TGF-β1
Codon 10 T/C
CC genotype
1.225
0.322–4.667
0.964
Codon 25 G/C
C allele
—
—
1.000
C-509T
TT genotype
0.719
0.203–2.543
0.844
9
CRP
T-717C
C allele
1.474
0.268–8.092
0.993
G1059C
C allele
2.289
0.349–15.010
0.686
C1444T
T allele
0.926
0.228–3.765
0.804
C1846T
TT genotype
1.067
0.358–3.182
0.908
10
HNF1α
Ileu27Leu
Leu/Leu genotype
0.857
0.318–2.310
0.760
Ala98Val
Val allele
—
—
1.000
11
Adiponectin
T45G
G allele
2.000
0.659–6.066
0.341
G276T
T allele
0.889
0.236–3.351
0.869
12
PPARα
Val227Ala
Ala allele
—
—
1.000
13
PPARγ
Pro12Ala
Ala allele
2.000
0.115–34.824
0.866
C161T
T allele
2.036
0.518–7.995
0.565
14
PPARγ coactivator1
Gly482Ser
Ser/ser genotype
3.250
0.480–21.998
0.438
G394A
A allele
0.381
0.073–1.992
0.449
15
Clock gene
T3111C
C allele
—
—
0.876
16
ACE
I/D
Deletion
1.270
0.381–4.230
0.697
17
ATIIR
A1166C
C allele
0.454
0.105–1.955
0.464
18
KCNJ11
E23K
A allele
0.571
0.185–1.765
0.329
19
SUR1
C-3T
TT genotype
0.286
0.081–1.008
0.946
20
UGT1A1
Promoter TA-repeat
*
6 allele
0.729
0.299–1.777
0.486
21
UGT1A6*2
*
1/
*
2
*
2 allele
0.955
0.255–3.576
0.789
22
UGT1A7
Codon 208
*
1/
*
3
*
3 allele
1.280
0.228–7.187
0.873
23
UGT1A8*2
codon173 A/G
GG genotype
1.176
0.507–2.732
0.705
24
UGT1A8*3
codon277 C/Y
Y allele
—
—
1.000
25
UGT1A9
C-2152T
T allele
—
—
1.000
T-275A
A allele
—
—
1.000
C1399T
TT genotype
1.126
0.485–2.617
0.783
26
UGT1A9*3
T98C
C allele
—
—
1.000
27
UGT2B7
C802T
T allele
0.770
0.330–1.795
0.545
28
CYP2C9*2
C430T
T allele
—
—
1.000
29
CYP2C9*3
A1075C
C allele
2.741
0.715–10.509
0.242
30
CYP2C19
*
1/
*
2/
*
3
*
2/
*
2,
*
2/
*
3,
*
3/
*
3
0.697
0.220–2.208
0.739
31
CYP3A4
*
1/
*
18
*
18 allele
—
—
1.000
G20230A
A allele
0.551
0.235–1.294
0.169
32
CYP3A5
A6985G
GG genotype
1.815
0.773–4.263
0.169
33
MDR-1
C1236T
TT genotype
1.067
0.291–3.916
0.814
C3435T
T allele
0.868
0.200–3.766
0.850
G2677T·A
T or A allele
0.688
0.152–3.102
0.922
34
OATP1B1
A388G
GG genotype
1.143
0.482–2.712
0.762
G455A
A allele
—
—
1.000
T521C
C allele
0.593
0.226–1.551
0.284
G721A
A allele
—
—
1.000
35
OATP1B3
T334G
GG genotype
1.176
0.507–2.732
0.705
G699A
AA genotype
0.714
0.242–2.108
0.542
Deletion A
Deletion
1.309
0.310–5.534
0.714
36
OATP2B1
*
1/
*
3
*
3 allele
0.936
0.402–2.176
0.877
37
Glucocorticoid receptor
Bcl I C/G
G allele
3.375
1.568–7.266
0.001
ER22/23EK
EK allele
—
—
1.000
N363S
S allele
—
—
1.000
38
CES2
rs2303218
AA genotype
2.700
0.697–10.465
0.146
rs3890213
A allele
3.429
0.791–14.854
0.190
IL, interleukin; TNF, tumor necrosis factor; INF, interferon; TGF, transforming growth factor; CRP, C-reactive protein; HNF, hepatocyte nuclear factor; PPAR, peroxisome proliferator-activated receptor; ACE, angiotensin-converting enzyme; ATIIR, angiotensin type 2 receptor; KCNJ, potassium inwardly rectifying channel, subfamily J; SUR, sulfonylurea receptor; UGT, uridine diphosphate-glucuronosyltransferase; CYP, cytochrome P450; MDR, multidrug resistance; OATP, organic anion transporting polypeptide; CES, carboxylesterase; OR, odds ratio; CI, confidence interval.


## 3.4. Multivariate Analysis

In the univariate analysis, female gender, dose per body weight of steroid and MMF, andNR3C1 Bcl1 G allele were associated with dyslipidemia. Multivariate analyses of the genotype data further supported the correlation of the presence of theNR3C1 Bcl1 G allele (odds ratio, 4.671, P
=
0.025) with dyslipidemia (Table 4).Table 4
Multivariate analysis of risk factors for dyslipidemia.
Factors
Categories
Univariate
Multivariate
OR
P
OR
95% CI
P
NR3C1 Bcl I
G allele
4.607
0.001
4.671
1.795–12.156
0.025
MMF/BW
≥24.2
2.902
0.027
2.212
0.771–6.350
0.375
Steroid/BW
≥0.188
2.526
0.034
1.126
0.389–3.256
0.843
Gender
Female
2.494
0.021
1.779
0.633–5.000
0.878
NR3C1, glucocorticoid receptor; BW, body weight; MMF, mycophenolate mofetil; OR, odds ratio; CI, confidence interval.


## 4. Discussion

The prevalence of dyslipidemia in renal transplant recipients is highly variable, having been previously reported to range from 44% to 80% [1]. Such variations are thought to be due to differences in the background of the patients or differences in the diagnostic criteria used to define dyslipidemia. Diagnosis of dyslipidemia has traditionally been based on TC, LDL and HDL cholesterol, and TG levels. However, TC levels are not associated with an increased risk of cardiovascular disease in the Japanese population, and therefore, LDL, HDL, and TG levels but not TC values are used as diagnostic criteria in Japan [30]. Given that the criteria may be different among previous reports, careful consideration is needed when results are compared among studies [31].Improvement in the diagnosis of dyslipidemia will ultimately rely on a unified set of diagnostic criteria to evaluate the presence of the disease. After kidney transplantation, the prevalence of dyslipidemia has been demonstrated to increase over time [5]. However, in somewhat of disagreement, a second study reported that the rate of dyslipidemia decreased after one year after transplantation [32]. These two studies highlight the importance of carefully considering the diagnostic criteria and timeframe in which the evaluation takes place. In this study, patients that presented with LDL cholesterol levels above 140 mg/dL, TC levels above 150 mg/dL, and HDL cholesterol levels below 40 mg/dL in the first year after transplantation, or patients requiring the administration of an oral statin, were diagnosed as having dyslipidemia [30]. Using these criteria, the prevalence of dyslipidemia was found to be 34.9%.Genetic polymorphisms have been previously investigated in association with renal transplantation, including the development of secondary complications such as diabetes [25] and hyperuricemia [33], as well as their role in the metabolism of immunosuppressive drugs [14]. In multifactorial diseases such as dyslipidemia, genetic polymorphism in genes associated with the disease likely influences the susceptibility towards disease progression. Understanding the association between such polymorphism and the disease could lead to the implementation of genetic tests that predict the risk of developing the disease [25, 33]. In this study, 60 polymorphisms in 38 genes were examined, from which the frequency of the G allele in theNR3C1 Bcl1 gene was found to be higher in patients with dyslipidemia. The glucocorticoid receptor, which is also known as nuclear receptor subfamily 3, group C, member 1 (NR3C1), is a main regulatory receptor at the hypothalamic-pituitary-adrenal axis. Glucocorticoids regulate the release of glucose from cells in order to supply the body response to face environmental stress. They also induce insulin resistance directly by perturbing insulin signal transduction via glucocorticoid receptor and indirectly by promoting visceral fat deposition and loss of lean mass [34]. In theNR3C1 Bcl1 G allele carriers, variation in this receptor was associated with obesity, hypertension, and diabetes [35, 36]. Additionally,NR3C1 Bcl1 GG genotype was significantly associated with an increased risk of metabolic syndrome and high BMI in Chinese population [37, 38]. It is possible that increased sensitivity of the glucocorticoid receptor [39] has an influence on the development of dyslipidemia [40]; nevertheless, no difference was observed in the steroid pharmacokinetics. Although a level of significance was achieved, the genetic analysis should be interpreted with caution. When multiple testing parameters are taken into account by applying Bonferroni correction (adjusted P value < 0.0008 based on 60 single nucleotide polymorphisms analyzed), none of the polymorphisms reached a level of statistical significance. This is not necessarily surprising, given that the study was performed retrospectively and made use of limited patient data and samples that were available. Future studies with a greater number of patients with predefined disease criteria will be important in determining the association of this polymorphism with dyslipidemia.Apart from theNR3C1 Bcl1 G allele, a number of predicted risk factors that were initially identified in the univariate analysis were not significantly associated with dyslipidemia when analyzed by multivariate analysis. It is likely that the gender of the patient would have been a confounding factor of the dose of immunosuppressive drugs administered; as pharmacokinetic monitoring of steroids and MMF is not common practice, a fixed dose was administered to all renal transplant recipients regardless of gender or body weight. Consequently, a larger dose per body weight of steroid and MMF would have been administered to women. Conversely, the fact that the area under the concentration, which was an effective pharmacokinetic marker of steroid and MMF treatment [41], was not found to be a significant factor in the multivariate analysis was quite reasonable.


## 5. Conclusion

The prevalence of dyslipidemia was found to be 34.9% in the Japanese cohort analyzed. The pharmacokinetics profiles of TAC, MMF, and steroid were not associated with the development of dyslipidemia under the same TAC-based immunosuppression treatment. However, the frequency of theNR3C1 Bcl1 G allele was found to be higher in patients having dyslipidemia and therefore may be a putative genetic marker for predicting risk of the disease. Although the mechanism by which theNR3C1 Bcl1 G allele might be involved in the prevalence of dyslipidemia is not clear, the analysis of dyslipidemia-related polymorphisms may provide a means to predict patient’s risk for having dyslipidemia. Further studies with a larger number of subjects are needed to validate the genetic risk factors associated with the prevalence of dyslipidemia and, in particular, the association ofNR3C1 Bcl1 genotypes.



---

*Source: 179434-2015-04-06.xml*